Philips highlights advances in imaging and physiology to support complex PCI at EuroPCR 2026

Article content

Additional solutions include a broad portfolio of interventional devices and imaging technologies supporting coronary and structural heart procedures.

Article content

Reducing radiation exposure
Reducing radiation exposure remains a central focus in image-guided therapy. Philips’ approach combines advanced imaging technologies, real-time feedback and workflow integration to minimize dose while maintaining image quality. Innovations such as SmartIQ built on a long-standing strategy to reduce radiation at the source, complemented by solutions such as instantaneous wave-free ratio (iFR) and intravascular ultrasound (IVUS) next to image fusion technologies that can reduce reliance on continuous fluoroscopy. Together, these approaches support safer working environments in the cath lab and contribute to long-term efforts to reduce occupational exposure for clinical teams and their patients.

Article content

Philips’ presence at EuroPCR 2026 will also feature scientific sessions and hands-on education to support the use of advanced techniques in daily practice. Key highlights include:

Article content

Article content

Article content

In addition, a comprehensive training village program will offer hands-on sessions in IVUS-guided PCI, co-registration techniques, and complex case planning led by experienced clinicians.

Article content

“Interventional cardiology teams are managing increasing procedural complexity while also prioritizing radiation safety,” said Mark Stoffels, Business Leader Image-Guided Therapy Systems at Philips. “By combining imaging, physiology and AI-enabled guidance with advanced dose reduction technologies, we aim to support clinicians in delivering efficient, high-quality care while helping protect both patients and staff.”

Article content

Article content

For more information about Philips’ cardiology solutions and activities at EuroPCR 2026, visit the Philips EuroPCR website or attend Philips sessions and demonstrations in Paris.

Article content

[1] Compared with the low ClarityIQ setting on Azurion systems, SmartIQ ultra-low left coronary 15 fps cine runs specify average reference air kerma reductions of 58% on Azurion M12 and 62% on Azurion M20 across all field sizes as stated in the IFU.
[2] Data on file at Philips IGTD: D001931792_B Usability Summative Evaluation Report
[3] Data on file at Philips IGTD: REF00942v2

Article content

For further information, please contact:

Article content

Article content

About Royal Philips 

Article content

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Article content

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2025 sales of EUR 18 billion and employs approximately 64,300 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Article content

Attachments

Article content

Article content

Article content

Article content

Article content

Article content

Article content